We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · December 07, 2022

IOP-Lowering Effect of Ripasudil–Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine Monotherapy

American Journal of Ophthalmology


Additional Info

American Journal of Ophthalmology
Ripasudil-brimonidine Fixed-dose Combination vs. Ripasudil or Brimonidine; Two Phase 3 Randomized Clinical Trials
Am J Ophthalmol 2022 Nov 18;[EPub Ahead of Print], H Tanihara, T Yamamoto, M Aihara, K Kawakita, S Kojima, M Kanazawa, T Nojima, H Suganami

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading